Table 1.

Clinical information for patients with human immunodeficiency virus 1 (HIV-1) infection

				CD4+ T cells		CD4+ T-cell nadir		CD8+ T cells
Patients	Sex (% male)	Age (years)	Viral load (log copies/ml)	Count (cells/μl)	Percentage	Count (cells/μl)	Percentage	Count (cells/μl)	Percentage
HAART-treated [mean ± SD (range)]	100	41 ± 13 (27–74)	≤ DL	841 ± 77 (497–1274)	34·7 ± 6·2 (22·5–45·1)	431 ± 119 (241–645)	23·6 ± 6·4 (17·9–38·0)	962 ± 418 (400–1710)	39·1 ± 11·0 (23·2–62·5)
Untreated [mean ± SD (range)]	78	37 ± 9 (26–62)	4·29 ± 0·71 (2·97–5·30)	626 ± 172 (297–996)	27·4 ± 6·8 (12·5–38·2)	471 ± 143 (210–920)	25·5 ± 8·3 (12·5–40·1)	1,189 ± 519 (381–2338)	48·8 ± 10·1 (31·1–74·0)

Thirty-six per cent of patients were successfully treated with highly active antiretroviral therapy (HAART). Of these, six of 13 patients (46%) were on a protease-inhibitor-containing HAART regimen. Two of 36 patients were coinfected with hepatitis C virus and one with hepatitis B virus. Just one patient was coinfected with both hepatitis B and C viruses. Sexual contact was the most frequently reported risk factor for acquiring HIV-1 infection (31 of 36 patients).

DL, detection limit; SD, standard deviation.